Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Other Non-Current Assets (2020 - 2025)

Historic Other Non-Current Assets for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $2.6 million.

  • Tarsus Pharmaceuticals' Other Non-Current Assets rose 18862.61% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 18862.61%. This contributed to the annual value of $2.6 million for FY2024, which is 6922.06% up from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported Other Non-Current Assets of $2.6 million as of Q3 2025, which was up 18862.61% from $2.6 million recorded in Q2 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' Other Non-Current Assets peaked at $2.6 million during Q1 2025, and registered a low of $529000.0 during Q1 2023.
  • For the 5-year period, Tarsus Pharmaceuticals' Other Non-Current Assets averaged around $1.4 million, with its median value being $1.3 million (2024).
  • Per our database at Business Quant, Tarsus Pharmaceuticals' Other Non-Current Assets surged by 129012.35% in 2021 and then tumbled by 6390.09% in 2022.
  • Over the past 5 years, Tarsus Pharmaceuticals' Other Non-Current Assets (Quarter) stood at $1.1 million in 2021, then crashed by 48.05% to $585000.0 in 2022, then surged by 158.8% to $1.5 million in 2023, then skyrocketed by 69.22% to $2.6 million in 2024, then grew by 0.04% to $2.6 million in 2025.
  • Its last three reported values are $2.6 million in Q3 2025, $2.6 million for Q2 2025, and $2.6 million during Q1 2025.